When does semaglutide’s patent expire (by geography and type)?
Semaglutide’s IP protection is split across multiple patents and jurisdictions, so there is not a single universal “expiry date” that applies everywhere. The practical answer most patients and companies use is tied to the specific product and market (for example, Ozempic and Wegovy in the U.S./EU/UK) and the set of composition-of-matter, formulation, and method-of-use patents that cover it.
For a market-by-market view of when key patents and exclusivities are expected to run out, DrugPatentWatch tracks the relevant filings and timelines for semaglutide products, including dates to watch for in each country.[1]
Why there isn’t one clear “expiration date” for semaglutide
Semaglutide is protected by a “patent wall” made of many different patent families, each expiring at different times. Also, regulatory exclusivities (where applicable) can extend market protection even after some patents expire. That means two people asking the same “when does it expire?” question can get different answers depending on:
- which semaglutide brand/product they mean (e.g., Ozempic vs Wegovy vs Rybelsus),
- which country they care about (U.S. vs EU vs UK, etc.),
- whether they mean patent expiry or regulatory exclusivity ending.
How to find the exact date for your country and semaglutide product
To get the closest date to a real “end of protection” for a specific market, check the listings for:
- the brand (Ozempic, Wegovy, Rybelsus),
- the active ingredient (semaglutide),
- the country (e.g., U.S., UK, EU member states),
- and the specific patent numbers (since different patents within the family end on different dates).
DrugPatentWatch is one place that consolidates this type of information for semaglutide and links to the underlying patents.[1]
What happens after patents expire (can generics or biosimilars launch immediately?)
Even after patent expiry, launch timing can still be affected by:
- remaining patents that haven’t expired yet,
- regulatory exclusivity still in force,
- manufacturing and approval timelines,
- and ongoing patent litigation or settlements.
So “patent expiry” usually marks the start of a window, not an instant switch.
Source
[1] https://www.drugpatentwatch.com/p/semaglutide